EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity

Ania M Jastreboff iD, Lee M Kaplan, Melanie J Davies, John P H Wilding, Nadia N Ahmad, Megan Murray iD, Yu Du, Nune Makarova, Kathryn Giblin, Nanette C Schloot, Yan Wang, TRIUMPH-1 Investigators

New England Journal of Medicine · 05.11.2026 · 395 (18) · 1781-1793

DOI: 10.1056/nejmoa2604169 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.11.2026. Verfasst von Ania M Jastreboff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityReceptors, Gastrointestinal HormoneReceptors, GlucagonAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodFatty AcidsInjections, SubcutaneousIntention to Treat AnalysisOsteoarthritis, KneePeptidesSleep Apnea, ObstructiveWeight LossSeverity of Illness IndexPain MeasurementTreatment Outcome

Substanzen

Anti-Obesity AgentsFatty Acidsgastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 Receptor AgonistsPeptidesReceptors, Gastrointestinal HormoneReceptors, Glucagonretatrutide

Autor:innen und Institutionen

  • Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, CT.
  • Department of Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT.
  • Yale Obesity Research Center (Y-Weight), Yale University School of Medicine, New Haven, CT.
  • Obesity and Metabolism Institute, Boston.
  • Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.
  • NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.

ORCID-Profile: Ania M Jastreboff, Megan Murray

Förderung

  • Eli Lilly and Company

Zitieren

APA

Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M., Du, Y., Makarova, N., Giblin, K., Schloot, N. C., Wang, Y., & TRIUMPH-1 Investigators (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, 395(18), 1781-1793. https://doi.org/10.1056/nejmoa2604169

Vancouver

Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026;395(18):1781-1793. doi:10.1056/nejmoa2604169

BibTeX
@article{Jastreboff2026,
  author = {Jastreboff, Ania M and Kaplan, Lee M and Davies, Melanie J and Wilding, John P H and Ahmad, Nadia N and Murray, Megan and Du, Yu and Makarova, Nune and Giblin, Kathryn and Schloot, Nanette C and Wang, Yan and TRIUMPH-1 Investigators, TRIUMPH-1 Investigators},
  title = {Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {18},
  pages = {1781--1793},
  doi = {10.1056/nejmoa2604169}
}
Kostenlos starten →